CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 34 enrolled
Drug / intervention
MK-1775 +2 moredrug
Likely dose
Gemcitabine 1000mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02037230
NCT02037230Phase 2Completed
CompareCT.gov

DOSE ESCALATION TRIAL OF THE Wee1 INHIBITOR AZD1775, IN COMBINATION WITH GEMCITABINE (+RADIATION) FOR PATIENTS WITH UNRESECTABLE ADENOCARCINOMA OF THE PANCREAS

University of Michigan Rogel Cancer Center·interventional·Posted Jan 15, 2014·Updated Feb 17, 2020

In Brief

A Phase 2 clinical trial evaluating MK-1775, Gemcitabine, and 1 other intervention for Adenocarcinoma of the Pancreas. Completed, enrolled 34 participants across 1 site.

Detailed Summary

The investigators' long-term goal is to improve the survival of patients with pancreatic cancer by enhancing the efficacy of gemcitabine-radiation by adding the Wee1 inhibitor MK-1775.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Pancreas
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 15, 2014
Enrollment StartJan 1, 2014
Primary CompletionAug 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 12.5 years ago

Interventions

MK-1775drug

MK-1775 will be given as an oral capsule on days 1 and 2, and on days 8 and 9 of every 3-week cycle .

Gemcitabinedrug

Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1 and 8 of a 3 -week treatment cycle.

Radiation Therapyradiation

52.5Gy in 25 fractions (2.1Gy/fraction), using intensity modulated radiation therapy (IMRT). Radiation therapy will be administered after chemotherapy.